Patient disposition
A total of 104 patients received SC brazikumab 210 mg during the open-label period, of whom 52 previously received placebo (placebo/brazikumab group) and 52 previously received brazikumab (brazikumab/brazikumab group) during the 12-week double-blind phase (Fig. Patient disposition. BRZ, brazikumab; IV, intravenous; OL, open-label; PBO, placebo; SC, subcutaneous